Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Abstract

The current paradigm in the amyloid hypothesis brands small β-amyloid (Aβ) oligomers as the toxic species in Alzheimer's disease (AD). These oligomers are fibril-like; contain β-sheet structure, and present exposed hydrophobic surface. Oligomers with this motif are capable of penetrating the cell membrane, gathering to form toxic ion channels. Current agents suppressing precursor Aβ cleavage have only met partial success; and to date, those targeting the peptides and their assemblies in the aqueous environment of the extracellular space largely fail in clinical trials. One possible reason is failure to reach membrane-embedded targets of disease-'infected' cells. Here we provide an overview, point to the need to account for the lipid environment when aiming to prevent the formation of toxic channels, and propose a combination therapy to target the species spectrum.

DOI: 10.1039/c3cp00017f
02004006002014201520162017
Citations per Year

627 Citations

Semantic Scholar estimates that this publication has 627 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Jang2013AlzheimersDW, title={Alzheimer's disease: which type of amyloid-preventing drug agents to employ?}, author={Hyunbum Jang and Laura S. Connelly and Fernando Ter{\'a}n Arce and Srinivasan Ramachandran and Ratnesh Lal and Bruce L. Kagan and Ruth Nussinov}, journal={Physical chemistry chemical physics : PCCP}, year={2013}, volume={15 23}, pages={8868-77} }